ACADIA Pharmaceuticals misses by $0.03, beats on revs; reaffirms May 1 PDUFA for NUPLAZID :
- Reports Q4 (Dec) loss of $0.45 per share, $0.03 worse than the Capital IQ Consensus of ($0.42); revenues fell 63.8% year/year to $0.02 mln vs the $0 mln Capital IQ Consensus.
- At December 31, 2015, ACADIA's cash, cash equivalents, and investment securities totaled $215.1 million compared to $322.5 million at December 31, 2014. Net proceeds of approximately $281.6 million received from ACADIA's follow-on public offering in January 2016 are not reflected in the balance sheet as of December 31, 2015.
No comments:
Post a Comment